Effect of magnesium sulfate on renal colic pain

Chen, Liang Fu; Yang, Chih Hao; Lin, Ting; Pao, Po Jia; Chu, Karen Chia Wen; Hsu, Chin Wang; Bai, Chyi Huey; Du, Ming; Hsu, Yuan Pin

doi:10.1097/md.0000000000023279

Cited by 8 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 315 articles were identified; 226 articles were discarded (not conforming to the inclusion criteria). Eighty RCTs and 8 systematic reviews [ 10 , 13 , 27 , 28 , 29 , 30 , 31 , 32 ] were appropriate for this review (adequacy of the abstract with the review: exploration of the efficacy of Mg in pain and consumption of analgesics) ( Figure 1 ). Pain reduction was assessed by visual analogue scale (VAS) (0 no pain—10 (or 100) worst possible), and evaluated at different times, or with questionnaires specific to the pathology as described further.…”

Section: Resultsmentioning

confidence: 99%

Magnesium for Pain Treatment in 2021? State of the Art

et al. 2021

View full text Add to dashboard Cite

Background: Magnesium (Mg) is commonly used in clinical practice for acute and chronic pain and has been reported to reduce pain intensity and analgesics consumption in a number of studies. Results are, however, contested. Objectives: This review aims to investigate randomised clinical trials (RCTs) on the effectiveness of Mg treatment on pain and analgesics consumption in situations including post-operative pain, migraine, renal pain, chronic pain, neuropathic pain and fibromyalgia. Results: The literature search identified 81 RCTs (n = 5447 patients) on Mg treatment in pain (50 RCTs in post-operative pain, 18 RCTs in migraine, 5 RCTs in renal pain, 6 RCTs in chronic/neuropathic pain, 2 RCTs in fibromyalgia). Conclusion: The level of evidence for the efficacy of Mg in reducing pain and analgesics consumption is globally modest and studies are not very numerous in chronic pain. A number of gaps have been identified in the literature that need to be addressed especially in methodology, rheumatic disease, and cancer. Additional clinical trials are needed to achieve a sufficient level of evidence and to better optimize the use of Mg for pain and pain comorbidities in order to improve the quality of life of patients who are in pain.

show abstract

Section: Resultsmentioning

confidence: 99%

Magnesium for Pain Treatment in 2021? State of the Art

et al. 2021

View full text Add to dashboard Cite

show abstract

“…1 From a physiological perspective, magnesium serves as a natural intracellular calcium antagonist, exerting its regulatory influence at the motor end-plate of neurons and across various muscle fiber types. 2 Magnesium sulfate competes with calcium, leading to the suppression of NMDA receptors in the brain. 2,3 These receptors get triggered by oxygen-deprived pressure and enable calcium to flow into the nerve cells, resulting in irreversible cellular harm.…”

Section: Introductionmentioning

confidence: 99%

“…2 Magnesium sulfate competes with calcium, leading to the suppression of NMDA receptors in the brain. 2,3 These receptors get triggered by oxygen-deprived pressure and enable calcium to flow into the nerve cells, resulting in irreversible cellular harm. 4 Abnormalities in magnesium concentrations, such as hypomagnesemia, can lead to disruptions in nearly all bodily systems and potentially give rise to life-threatening issues like ventricular arrhythmia, coronary artery vasospasm, and sudden death.…”

Section: Introductionmentioning

confidence: 99%

Frequency of hypomagnemsemia in neonate with hypocalcemic seizures presenting to a Tertiary Care Hospital.

Waqar Ahmed,

Aisha Kiran,

Fareeda

et al. 2024

TPMJ

View full text Add to dashboard Cite

Objective: To determine the frequency of hypomagnesemia in neonate with hypocalcemic seizures presenting to a tertiary care hospital. Study Design: Cross-sectional Descriptive Study. Setting: Ghulam Muhammad Mahar Medical College Hospital in Sukkur. Period: 1st May 2022 to 31st October 2022. Material & Methods: The research involved a group of 157 infants who had experienced seizures due to low calcium levels. A proficient phlebotomist with over two years of experience drew a 3cc venous blood sample from each participant, which was subsequently sent to the hospital laboratory for analysis. The serum magnesium levels were determined, and hypomagnesemia was defined as a magnesium level below 1.7mg/dl. These findings were meticulously documented in the attached annexure proforma. Results: A total of 157 infants presented with hypocalcemic seizures were included in this study. The average age of the infants was 6.31±4.62 days. Frequency of hypomagnesemia in neonate with hypocalcemic seizures was 28.9% (44/157) infants. The data indicates that exclusively breastfed neonates have the highest prevalence of hypomagnesaemia at 41%, while those exclusively formula fed have the lowest at 22.2%. However, the p-value of 0.110 suggests that these differences are not statistically significant, indicating that feeding status may not be a major contributor to hypomagnesaemia in neonates. The prevalence of hypomagnesaemia is higher in the 6.6-7 mg/dl range (31.7%) compared to the 5-6.5 mg/dl range (25.5%). Conclusion: In our research, the occurrence of low magnesium levels in newborns experiencing seizures due to low calcium levels is more prevalent among infants. This typically indicates the presence of both vitamin D deficiency and hypomagnesemia simultaneously, and can be effectively addressed with short-term therapy. Newborns who have seizures and are diagnosed with low calcium levels are unlikely to gain any advantages from neuroimaging assessments.

show abstract